Truist raised the firm’s price target on Stryker (SYK) to $400 from $390 and keeps a Hold rating on the shares. The company delivered another double-digit organic sales and EPS growth performance despite an incremental $200M in tariff headwinds, the analyst tells investors in a research note. Stryker also boasts a premium revenue growth profile in large-cap MedTech, with several new launch areas set to build momentum, the firm adds.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $450 from $440 at Bernstein
- Stryker’s Strong Performance and Growth Potential Justify Buy Rating
- Stryker Corp’s Earnings Call Highlights Robust Growth
- Stryker price target raised to $456 from $405 at Roth Capital
- Stryker’s Strong Financial Performance and Strategic Positioning Justify Buy Rating